Viking Therapeutics Faces Critical November Data Reveal

The coming weeks represent a pivotal moment for Viking Therapeutics as the biotech firm prepares to unveil fresh clinical data for its promising obesity treatment, VK2735. While market anticipation has driven recent share gains, the company's latest financial results present a more sobering picture of its current standing.

Viking Therapeutics reported a third-quarter 2025 loss of $0.81 per share, significantly wider than analysts had projected. The company's net loss reached $90.8 million during the period. As is typical for clinical-stage biopharmaceutical companies, Viking has not yet generated revenue from product sales. However, the firm maintains a solid cash position with $715 million in available funds as of September 30, providing substantial runway for ongoing development programs.

Share Rally Precedes Key Scientific Presentations

Investor enthusiasm propelled Viking's shares upward by 7.3% yesterday following the announcement of two major November presentations. The company will present new analyses from its Phase 2 VENTURE study at ObesityWeek 2025 (November 4-7, Atlanta) and the American Heart Association Scientific Sessions 2025 (November 7-10, New Orleans).

Should investors sell immediately? Or is it worth buying Viking Therapeutics?

Market attention will focus on VK2735's effects on prediabetes and metabolic syndrome. Additionally, Viking plans to disclose the design of its ongoing Phase 3 VANQUISH trials. The dual agonist compound, which targets both GLP-1 and GIP receptors, represents one of the most closely watched candidates in the competitive obesity drug market.

Make-or-Break Period for Obesity Drug Candidate

November's data presentations will likely determine the near-term trajectory for Viking's stock. The critical question facing investors is whether the clinical results will justify current market expectations. The company's fortunes remain heavily tied to the success of VK2735 across both its subcutaneous and oral formulations, with the biotech firm staking its future on this potential blockbuster treatment.